Mechanism of 1α,25-dihydroxyvitamin D3-dependent repression of interleukin-12B  by Gynther, Petra et al.
Biochimica et Biophysica Acta 1813 (2011) 810–818
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamcrMechanism of 1α,25-dihydroxyvitamin D3-dependent repression of interleukin-12B
Petra Gynther a, Sari Toropainen a, Juha M. Matilainen a, Sabine Seuter b,
Carsten Carlberg a,b, Sami Väisänen a,c,⁎
a Department of Biosciences, University of Eastern Finland, FI-70211 Kuopio, Finland
b Life Sciences Research Unit, University of Luxembourg, L-1511 Luxembourg, Luxembourg
c Turku Centre for Biotechnology, University of Turku FI-20521 Turku, FinlandAbbreviations: 1α,25(OH)2D3, 1α,25-dihydroxyvita
munoprecipitation; DR, direct repeat; ER, everted repea
Eagle Medium; FBS, fetal bovine serum; HDAC, hist
histone 3 trimethylated at lysine 27; H4ac, acetylated
lipopolysaccharide; NCOR, nuclear receptor co-repress
SMRT, silencing mediator for retinoid and thyroid hor
TLR, toll-like receptor; VDR, vitamin D receptor; VDRE,
⁎ Corresponding author at: Department of Biosciences
P.O. box 1627, FIN-70211 Kuopio, Finland. Tel.: +35
2811510.
E-mail address: Sami.Vaisanen@uef.ﬁ (S. Väisänen).
0167-4889/$ – see front matter © 2011 Elsevier B.V. A
doi:10.1016/j.bbamcr.2011.01.037a b s t r a c ta r t i c l e i n f oArticle history:
Received 24 September 2010
Received in revised form 18 January 2011
Accepted 31 January 2011
Available online 18 February 2011
Keywords:
Chromatin
IL-12B
VDR
Transcription
InﬂammationInterleukin 12 (IL-12) is a heterodimeric, pro-inﬂammatory cytokine that plays a central role in activation
and differentiation of CD4+ T cells into interferon-γ secreting T-helper type 1 cells. IL-12B, a gene encoding
the larger subunit of active IL-12, has been reported to be down-regulated by the nuclear hormone 1α,25-
dihydroxyvitamin D3 (1α,25(OH)2D3), but the mechanism of the regulation is unknown. In this study, we
have examined the molecular mechanism of transcriptional regulation of the IL-12B gene by 1α,25(OH)2D3
in lipopolysaccharide (LPS)-treated human monocytes (THP-1). Quantitative RT-PCR showed that IL-12B
mRNA displays a cyclical expression proﬁle and is down-regulated 2.8-fold during the ﬁrst 8 h and even
12.1-fold 24 h after exposure to 1α,25(OH)2D3. Gel shift and quantitative chromatin immunoprecipitation
(ChIP) assays demonstrated vitamin D receptor (VDR) binding to genomic regions 480 and 6300 bp
upstream of the IL-12B transcription start site (TSS). Quantitative ChIP assays also revealed that together
with VDR and its partner RXR the above regions recruited the co-repressor NCOR2/SMRT and histone
deacetylase 3 leading to a decreased histone 4 acetylation and increased histone 3 trimethylation at the IL-
12B promoter and its TSS. We suggest that these repressive epigenetic changes eventually cause down-
regulation of IL-12 expression.min D3; ChIP, chromatin im-
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Interleukin 12 (IL-12) is a heterodimeric, pro-inﬂammatory
cytokine that consists of two protein subunits, p40 and p35, that
are encoded by distinct genes and together form the biologically
active IL-12 cytokine, IL-12p70 [1]. Interestingly, p40 is also used as
a subunit of IL-23, which is another pro-inﬂammatory cytokine [2].
Both IL-12 and IL-23 are produced predominantly by local antigen-
presenting cells, such as activated monocytes, macrophages and
dendritic cells, in response to bacterial antigens and intracellular
pathogens via toll-like receptor 4 (TLR-4) signaling [2,3]. IL-12 plays
a central role in the activation and differentiation of CD4+ T cells
into interferon-γ secreting T-helper (Th) type 1 cells, while IL-23 is
essential for the survival and proliferation of IL-17 producing CD4+
memory Th17 cells [4,31,32].Although induction of IL-12 and IL-23 by intracellular pathogens
is indispensable to an efﬁcient immune response against microbial
infections, over-expression of IL-12 and/or IL-23 may lead to the
development and perpetuation of chronic inﬂammatory and
autoimmune diseases, such as rheumatoid arthritis, psoriasis,
multiple sclerosis, Crohn's disease and inﬂammatory bowel disease
[5,6,33,34]. To prevent the development of these serious diseases,
the production of IL-12 and IL-23 is normally tightly controlled by
multiple negative regulatory mechanisms. There are over 50
substances with reported IL-12B inhibitory effects [4], one of
which is 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3) that has
been reported to inhibit IL-12 production in activated macrophages
[7–9].
The seco-steroid hormone 1α,25(OH)2D3 is the biologically most
active metabolite of vitamin D3 that regulates calcium and bone
metabolism, controls growth and differentiation of multiple cell types
and plays an important role as an immuno-regulatory and anti-
inﬂammatory agent [10,11]. 1α,25(OH)2D3mediates its effects via the
vitamin D receptor (VDR), a ligand-activated transcription factor that
belongs to the superfamily of nuclear receptors [35]. VDR is expressed
in a number of different immune cells including dendritic cells and
macrophages [12]. In addition, activated macrophages are able to
synthesize and secrete 1α,25(OH)2D3, which further underlines the
potential of 1α,25(OH)2D3 in the regulation of immune responses
[13].
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with the retinoid X receptor (RXR). This leads to the association of
VDR–RXR heterodimeric complex with vitamin D response elements
(VDREs) within the regulatory regions of primary VDR target genes
and subsequently results in activation or repression of these genes.
VDREs are formed by direct repeats (DRs) of the hexameric consensus
sequence RGKTCA (R=A or G, K=G or T) with three or four
intervening nucleotides (DR3 and DR4) or by everted repeats (ERs)
with six to nine spacing nucleotides (ER6 to ER9) [14–16]. Although a
suppressing effect of 1α,25(OH)2D3 on IL-12 expression has been
reported [9,17], no functional VDREshave been foundwithin the genes
IL-12B or IL-12A. Instead, binding sites for NF-κB, C/EBP and AP-1 have
been identiﬁed at the proximal promoter of IL-12B, via which the
activation of IL-12 appears to happen [18–20]. The repressive effect of
1α,25(OH)2D3 has been associatedwith the proximal IL-12Bpromoter,
but no direct binding of VDR to this region has been reported [9].
In this study, we aimed to clarify the molecular mechanism of
1α,25(OH)2D3-dependent IL-12B repression in lipopolysaccharide
(LPS)-activated THP-1 human monocytic cells. Our data suggest that
the 1α,25(OH)2D3-dependent repression is mediated via VDREs that
locate upstream of the binding sites of NF-κB, C/EBP and AP-1.
Interestingly, the IL-12B repression involves cyclic recruitment of a
repressive protein complex that leads to a non-permissive chromatin
environment at the IL-12B promoter and TSS and ultimately to the
inhibition of IL-12 expression.
2. Materials and methods
2.1. Cell culture
THP-1 human acute monocytic leukemia cells were maintained in
RPMI-1640 medium (Sigma-Aldrich) and SW-480 human colon adeno-
carcinoma cells were cultured in Dulbecco's Modiﬁed Eagle Medium
(DMEM). Both media contained 10% fetal bovine serum (FBS), 2 mM L-
glutamine, 0.1 mg/ml streptomycin and100 U/ml penicillin and culturing
was in a humidiﬁed 95% air/5% CO2 incubator. Before use in experimental
procedures, FBS was stripped from lipophilic compounds, such as
endogenous nuclear receptor ligands, by stirring it with 5% activated
charcoal (Sigma-Aldrich) for 3 h at room temperature. Charcoal was then
removed by centrifugation, and the medium was sterilized by ﬁltration
(0.2 μm pore size). THP-1 and SW-480 cells were maintained for
experiments in phenol red-free DMEM, supplemented with 5% char-
coal-strippedFBS, 2 mML-glutamine, 0.1 mg/ml streptomycinand100 U/
ml penicillin. Prior to RNA or chromatin extraction, the cells were treated
with 100 ng/ml LPS for 24 h and then exposed to either solvent (ethanol,
0.1% ﬁnal concentration) or 10 nM 1α,25(OH)2D3 (Sigma-Aldrich).
2.2. Human monocyte isolation
The isolation of human primarymonocytes was essentially done as
indicated before [21]. In short, the peripheral bloodmononuclear cells
(PBMCs)were isolated by density gradient centrifugation using Ficoll-
Paque Plus (GE Healthcare) and Leucosep tubes (Greiner bio-one,
Wemmel, Belgium). The number of PBMC was determined using a
hematocytometer. The CD14+ cells weremagnetically labeled and the
cell suspension was loaded onto a MACS LS separation column
(Miltenyi Biotech, Utrecht, The Netherlands) in a magnetic ﬁeld and
eluted with MACS buffer from the column after washing and removal
of the column from the magnetic ﬁeld. The purity of the CD14+ cells
was evaluated by ﬂow cytometry using anti-CD14-FITC and anti-
IgG2a-FITC antibodies (ImmunoTools, Friesoythe, Germany) and a
FACSCantoII Flow Cytometry System (Becton Dickinson, Franklin
Lakes, NJ, USA). The number of the primary monocytes was
determined after which the cells were resuspended in pre-warmed
RPMI-1640 medium containing 5% human serum minus, 2 mM L-
glutamine, 0.1 mg/ml streptomycin and 100 U/ml penicillin to adensity of 2–3×106 cells/ml and incubated over night in a humidiﬁed
95% air/5% CO2 incubator. Then, ligand treatments were performed
followed by total RNA extraction.2.3. Total RNA extraction, cDNA synthesis and real-time quantitative PCR
Total RNA was extracted using High Pure RNA Isolation Kit (Roche)
and cDNA synthesiswasperformedusing TranscriptorHigh Fidelity cDNA
Synthesis Kit (Roche) according to the manufacturer's instructions. Real-
time quantitative PCR was performed with a LightCycler 480 apparatus
(Roche) using TaqMan Gene Expression Assays (Applied Biosystems,
Carlsbad, CA, USA) for IL-12B (Hs00233688_m1), TLR-4
(Hs00152939_m1) and RPLP0 (4,333,761 F) and Maxima™ Probe qPCR
Master Mix (Fermentas, Vilnius, Lithuania). PCR cycling conditions were:
10 min at 95 °C, followed by 50 cycles of 15 s at 95 °C and 60 s at 60 °C.
Fold changes were calculated using the formula 2−(ΔΔCt), where
ΔΔCt=ΔCt(1α,25(OH)2D3)−ΔCt(EtOH), and ΔCt=Ct(IL−12B)−Ct(RPLP0). Ct
is the cycle at which the threshold line is crossed. For statistical analysis,
fold changeswere log2-transformedand two-tailed Student's t-testswere
performed to calculate statistical signiﬁcancebetween solvent treated and
ligand-treated samples.2.4. siRNA silencing
THP-1 cellswere transfectedwith either non-speciﬁc siRNAoligomers
or Stealth™ siRNAs targeting VDR mRNA (Invitrogen, Carlsbad, CA, USA)
by using RNAiMAX reagent (Invitrogen) according to the manufacturer's
instructions. The cellswere seeded into 6-well plates andgrown inphenol
red-free DMEM supplemented with 5% charcoal-stripped FBS. Liposomes
containing control or VDR siRNAwere formed by incubating 100 pmol of
each siRNAduplexwith 5 μl of RNAiMAX for 20 min at room temperature
in a total volume of 500 μl of phenol red-free DMEMwithout antibiotics.
The liposomes were added to the cells and siRNA treatment was
continued for 48 h, then the cells were treated with 100 ng/ml LPS for
24 h and ﬁnally exposed to either solvent (ethanol, 0.1% ﬁnal concentra-
tion) or 10 nM1α,25(OH)2D3 for indicated time periods. Silencing of VDR
at the protein level was veriﬁed byWestern blotting using 25 μg of whole
cell extract from THP-1 cells and anti-VDR antibody (sc-1008, Santa Cruz
Biotechnology, Santa Cruz, CA, USA). Cellular proteins were separated
using 12% SDS polyacrylamide gel electrophoresis. The blotted proteins
were detected by using IR800 ﬂuorescence labeled secondary antibodies
(ThermoFisher Scientiﬁc,Waltham,MA,USA) andOdyssey reader (Li-Cor
Biosciences, Lincoln, NE, USA).2.5. Gel shift assay
VDR and RXR proteins were generated by coupled in vitro
transcription/translation reaction using full-length cDNAs subcloned
into the T7/SV40 promoter-driven pSG5 expression vector (Stratagene,
LaJolla, CA, USA) [34] and TNT Quick Coupled Transcription/Translation
Systems (Promega, Madison, WI, USA) according to the manufacturer's
instructions. Oligonucleotideswere labeledwith Klenow fragment DNA
polymerase (Fermentas) in the presence of a nucleotide mixture
containing [32P] α-dCTP. In gel shift assays, 10 ng of the appropriate in
vitro translated proteins were incubated for 15 min in a total volume of
20 μl of binding buffer (10 mM Hepes, pH 7.9, 150 mM KCl, 1 mM
dithiothreitol, 0.2 μg/μl of poly(dI-C), 5% glycerol). 1 ng of [32P]-labeled
double-stranded oligonucleotides were then added and incubation was
continued at room temperature for 20 min. Protein–DNA complexes
were resolved by electrophoresis through non-denaturing 5% (w/v)
polyacrylamide gels in 0.5×TBE (45 mM Tris, 45 mM boric acid, 1 mM
EDTA, pH 8.3) and quantiﬁed on a FLA-3000 reader (Fuji, Tokyo, Japan)
using Image Gauge software (Fuji).
Fig. 1. Expression proﬁling of the human IL-12B gene. Relative mRNA expression of IL-12Bwas measured by quantitative PCR in LPS-treated THP-1 cells after stimulation with 10 nM
1α,25(OH)2D3 for indicated time periods (A) and for primary monocytes after 6 h treatment with 100 nM 1α,25(OH)2D3 (B). (C) siRNA silencing of VDR at protein level was veriﬁed
byWestern blotting using whole-cell extracts from LPS-treated THP-1 cells. (D) Relative mRNA expression of IL-12Bwas measured after 6 h of 10 nM 1α,25(OH)2D3 treatment after
silencing of VDR. The results were normalized to the housekeeping gene RPLP0. (E) IL-12B expression at protein level was determined from cell culturing medium using ELISA. Two-
tailed Student's t-tests were performed to calculate p-values in reference to vehicle treatment (* pb0.05, ** pb0.01, *** pb0.001). In each panel, n is at least 3. Error bars indicate S.D.
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SW-480 cells were transfected with the pGL4 containing minimal
promoter of thymidine kinase (tk) gene and the upstream regions of the
human IL-12B gene. A construct containing the proximal promoter of
the human CYP24 gene with a cluster of DR3-type VDREs was used as a
positive control. SW-480 cells were transfected using DOTAP transfec-
tion protocol with a mixture of 1 μg of different reporter constructs and
1 μg of expression vector for human VDR gene (pSG5-hVDR) in a 6-well
plate format. After 5 h, 1α,25(OH)2D3 was added to 100 nM andluciferase reporter assay was performed 16 h post-treatment with
BriteLite luciferase substrate (Perkin Elmer, Waltham, MA, USA) in a
Victor3 multilabel counter (Perkin Elmer) equipped with automatic
dispenser. Luciferase activities were normalized with respect to total
protein concentration.
2.7. ELISA assays
For protein expression analysis, THP-1 cells (2×106 cells/ml) were
stimulatedwith1 μg/ml LPS for24 hprior to treatmentwitheither solvent
Fig. 2. ChIP scanning and in silico analysis of the IL-12B promoter. The region spanning the genomic region from−10,010 to +1938 bp relative to the IL-12B TSS was studied using
both ChIP with antibody against VDR (A) and in silico analysis (B) to reveal putative VDREs. Repetitive sequences are indicated by grey boxes and putative VDREs (RE1–RE6) by red
boxes. A detailed sequence comparison between human, rhesus monkey, mouse and dog sequences is shown for the studied elements.
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72 h, after which the cell culture supernatants containing secreted IL-12B
proteinwere collected. Theeffect of 1α,25(OH)2D3on theexpressionof IL-
12B at protein level was determined using Human IL-12/IL-23 p40 Dimer
Quantikine ELISA Kit (R&D Systems, NE, USA) according to the
manufacturer's instructions.
2.8. ChIP assays
For ChIP assays, nuclear proteins were cross-linked to DNA by
adding formaldehyde directly to the medium to a ﬁnal concentration
of 1% and incubating at room temperature for 10 min on a rocking
platform. Cross-linking was stopped by adding glycine to a ﬁnal
concentration of 0.125 M and incubating at room temperature for
5 min on a rocking platform. The medium was removed and the cells
were washed twice with ice-cold PBS. The cells were collected and
resuspended in lysis buffer containing protease inhibitors. The
chromatin was fragmented by sonication using Bioruptor (Diagenode,
Liège, Belgium) with adaptors for 15 min at 4 °C to result in DNA
fragments of 300 to 500 bp and non-speciﬁc background was removed
using salmon sperm DNA/protein A agarose slurry (Millipore,
Temecula, CA, USA) at 4 °C for 1 h. The recovered chromatin solutionswere diluted 1:10 (v/v) in ChIP dilution buffer and incubated with
1 μg of indicated antibodies at 4 °C overnight. Non-speciﬁc IgG (12–
370) and antibodies against histone H4 acetylated at K5, K8, K12 and
K16 (H4Ac, 06–598) and histone H3 trimethylated at K27
(H3K27me3, 17–622) were from Upstate Biotechnology (Lake Placid,
NY, USA), the antibodies against VDR (sc-1008), RXRα (sc-553),
NCOR2/SMRT (sc-1610), SRC1 (sc-8995) and HDAC3 (sc-11417) from
Santa Cruz Biotechnologies.The immuno-complexes were collected
using protein A agarose slurry (Millipore) and reverse cross-linked in
the presence of 2 μl of proteinase K (18.9–20.1 mg/ml) (Fermentas) at
64 °C overnight, after which phenol:chloroform extraction and ethanol
precipitation were performed. ChIP samples were analyzed with
quantitative PCR using BHQ1-FAM6 hydrolysis probes (Eurogentec,
Liege, Belgium) and Maxima™ Probe qPCR Master Mix.The sequences
of the primers and the hydrolysis probes are listed in Tables S1 and S2,
respectively. The qPCR reaction was performed with a LightCycler 480
apparatus using the same PCR proﬁle as with cDNA samples in an
appropriate annealing temperature. The results were normalized with
respect to input. Fold changes were calculated by using the formula
2−(ΔCt)⁎100(speciﬁc antibody)/2−(ΔCt)⁎100(non-speciﬁc IgG), where ΔCt is
Ct(immunoprecipitated DNA)−Ct(input) and Ct is the cycle at which the
threshold line is crossed.
Fig. 3. The ability of VDR–RXR heterodimer to associate with the putative VDREs. (A) Schematic presentation of locations and sequences of RE2 and RE5. Gel shift analysis was used to
study the binding of in vitro translated VDR and RXR to DR4-type element of rat Pit-1 (B) and RE2 (C) or RE5 (D) in the presence and absence of 1α,25(OH)2D3. NS indicates non-
speciﬁc complexes. Representative gels are shown. (E) 1α,25(OH)2D3 treatment enhanced the binding of VDR–RXR to the putative VDREs. (F) Percentage of protein-complexed DNA.
Two-tailed Student's t-tests were performed to calculate p-values in reference to solvent treated samples (* pb0.05, ** pb0.01). In each bar, n is at least 3. Error bars indicate S.D.
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3.1. Expression proﬁling of IL-12B and TLR-4 in THP-1 cells
The effect of 1α,25(OH)2D3 on the expression of IL-12B mRNA was
studied in THP-1 human acute monocytic leukemia cells using TaqMan
gene expression assays. Because the basal expression of IL-12B mRNA
was very low, the cells were primed using LPS for 24 h before ligand
treatments. This increased the basal expression and emphasized the
ligand effects (Fig. S1A). The IL-12B mRNA expression was measured
every 15 min up to 8 h and again 24 h after onset of 1α,25(OH)2D3
treatment (Fig. 1A). According to our data, 1α,25(OH)2D3 treatment
caused a signiﬁcant, up to 2.5-fold down-regulation of IL-12B mRNA
levels within the ﬁrst 6 h. Interestingly, the expression proﬁle showed a
cyclical behavior, having minima at time points 45 min, 105 min,
195 min, 270 min, 315 min, 360 min and 435 min. However, the lowest
expression was reached after 24 h with a 12.2-fold repression of basal
expression levels. The effect of 1α,25(OH)2D3 on IL-12B expression after
6 h was also examined in primary human monocytes (Fig. 1B). A
signiﬁcant 1.5-fold repression was observed, suggesting that the 1α,25
(OH)2D3-dependent repression of IL-12B is not only related to cultured
cells but also observable in primary cells.Because LPS induces IL-12B expression via TLR-4, we wanted to
conﬁrm that the observed repression of IL-12B did not result from
changes in TLR-4 signaling and therefore examined the effect of 1α,25
(OH)2D3 treatment to the TLR-4 expression using hormone treatment
times 270 min, 360 min and 450 min that resulted in strongest
repression of IL-12B. According to our data, the expression of TLR-4
did not change markedly due to 1α,25(OH)2D3 treatment although a
slight decrease could be observed at time point 450 min (Fig. S1B).
We repeated the expression assays using opposite order of
treatments to ﬁnd out, if the hormone treatment affected to the LPS
induction of IL-12B expression. Our data suggest that, when the cells
were treated with 1α,25(OH)2D3 prior to LPS treatment, TLR-4
expression did not change markedly (Fig. S1C). Instead, IL-12B
repression was even more prominent than with LPS pre-treatment
(Fig. S1D). Similar results were obtained when the experiment was
repeated with hormone treatment times of 270, 360 and 450 min
prior to LPS treatments (Fig. S1E). Thus, the 1α,25(OH)2D3 pre-
treatment appeared to suppress the induction of IL-12B by LPS.
To further verify that the observed repression of IL-12B mRNA
expression was dependent on VDR, we silenced VDR using siRNA
before measuring IL-12B expression. Silencing of VDR at protein level
was conﬁrmed by immuno-blotting (Fig. 1C). Non-speciﬁc control
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expression, whereas VDR-speciﬁc siRNA completely abolished it
(Fig. 1D).
The effect of 1α,25(OH)2D3 on the expression of IL-12B at protein
level was determined using ELISA. According to our data, 1α,25Fig. 4. Ligand treatment leads to cyclical recruitment of repressive protein complexes to
the IL-12B TSS and promoter. ChIP assays were performed using antibodies against
VDR, RXR, HDAC3 or NCOR2/SMRT with 10 min intervals of 10 nM 1α,25(OH)2D3
treatment up to 100 min in LPS-treated THP-1 cells. The IL-12B TSS is indicated in black
and the genomic regions containing RE2 and RE5 in red and blue, respectively. Two-
tailed Student's t-tests were performed to calculate p-values in reference to time point
0 (* pb0.05, ** pb0.01, *** pb0.001). In each panel, n is at least 3. Error bars indicate S.D.(OH)2D3 treatment caused small but signiﬁcant decrease in the
amount of secreted IL-12B when compared to vehicle treatment
(Fig. 1E). However, it should be noted that although IL-12B levels
slowly decreased, there was still a reasonable amount of secreted IL-
12B present in themedium after hormone treatments of 48 h and 72 h
suggesting that clearing of IL-12B from the medium is relatively slow.
In summary, in THP-1 cells IL-12B mRNA expression is down-
regulated in a cyclical fashion after short-term 1α,25(OH)2D3
treatment and the down-regulation can be observed also at protein
level suggesting that the IL-12B gene is a primary VDR target.
3.2. 1α,25(OH)2D3 treatment induces association of VDR with several
genomic regions of the IL-12B gene
In order to locate putative VDREs within the IL-12B gene, we
performed a ChIP scanning analysis with antibody against VDR
(Fig. 2A). In total, 22 overlapping PCR primer pairs were used that
covered the genomic region from −10,010 bp to +1938 bp relative
to the IL-12B TSS. Our data suggest that VDR was recruited ligand-
dependently to regions 5, 13, 17 and 20. The weaker VDR binding at
adjacent regions is likely due to a ﬂanking effect from active regions.
Although all four regions recruited VDR ligand-dependently, their
binding proﬁles were slightly different. Associationwith regions 5 and
17 reached a maximum 30 min after onset of ligand treatment,
whereas strongest binding of VDR to regions 13 and 20 could be
observed at time point 90 min.
An in silico analysis for hexameric nuclear recptor binding sites
using the net-based program NUBIScan [22] revealed that region 5
contains a DR3- and a DR4-type element (REs 1 and 2), region 13 an
ER8-type element (RE3), regions 16 and 17 two ER6-type elements
(REs 4 and 5) and region 20 a DR3-type element RE6 (Fig. 2B). A
sequence comparison between human, rhesus monkey, mouse and
dog shows that RE2 is highly conserved across different species, REs 1,
3 and 6 are conserved excluding the mouse and REs 4 and 5 are
speciﬁc for primates.
Taken together, within 10 kB of the IL-12B promoter four VDR
binding regions (5, 13, 17 and 20) were identiﬁed, which together
contain six putative VDREs (REs 1–6).
3.3. Functionality of the putative VDREs of the IL-12B promoter
In order to determine, whether the VDR associated genomic
regions of the IL-12B promoter contain any functional VDREs, we
cloned them in front of the luciferase gene and performed reporter
gene analysis (Fig. S3). Due to very low transfection efﬁciency of THP-
1 cells, we had to shift the cellular system to SW-480 human colon
adenocarcinoma cells. Although SW-480 cells also express TLR-4 (as a
mediator of LPS effects), the basal IL-12B mRNA expression in these
cells was clearly lower than in THP-1 cells (Fig. S2A). However, also in
SW-480 cells 1α,25(OH)2D3 treatment caused cyclical repression of
IL-12B mRNA expression (Fig. S2B). This suggests that SW-480 cells
are suitable in depicting the functionality of putative VDREs in the
regulation of the IL-12B gene.
The positive control of the reporter gene analysis, the proximal
promoter of human CYP24 gene, was 7.4-fold inducible by 1α,25
(OH)2D3 (Fig. S3). In contrast, the basal activities of reporter
constructs containing REs 1 and 2 (region 5) or REs 4 and 5 (region
Fig. 5. Ligand-dependent epigenetic changes at the IL-12B promoter and the TSS. ChIP
assays were performed using antibodies against H3K27me3 and H4ac with 10 min
intervals of 10 nM 1α,25(OH)2D3 treatment up to 100 min in LPS-treated THP-1 cells.
The IL-12B TSS is indicated in black and the genomic regions containing RE2 and RE5 in
red and blue, respectively. Two-tailed Student's t-tests were performed to calculate p-
values in reference to time point 0 (* pb0.05, ** pb0.01). In each panel, n is at least 3.
Error bars indicate S.D.
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region 17 mediated a 3-fold higher basal activity than the empty
cloning vector. This could be a sign that in the absence of 1α,25
(OH)2D3 this genomic region may have an activating effect on IL-12B
expression. Region 13 (containing RE3) also caused repression in
response to 1α,25(OH)2D3 treatment although not signiﬁcant. The
construct containing region 20 showed no signiﬁcant response to
1α,25(OH)2D3 and thus the putative element RE6 was omitted from
further studies.
The ability of the putative VDREs 1–5 (for sequences see Figs. 3A
and S4A) within regions 5, 13 and 17 to associate with in vitro
translated VDR–RXR heterodimers was examined using gel shift
analysis. Compared with the positive control, the established VDRE of
the rat Pit-1 gene (gaAGTTCAtgagAGTTCA) [15] (Fig. 3B), RE2was able
to bind VDR–RXR heterodimers even more efﬁciently (Fig. 3C), while
the binding to RE5 was signiﬁcantly weaker (Fig. 3D). Moreover, the
binding of VDR–RXR heterodimers to the reference RE and REs 2 and 5
increased signiﬁcantly in the presence of 1α,25(OH)2D3, but not
statistically signiﬁcantly in case of RE5 (Fig. 3E). REs 1, 3 and 4 showed
no detectable binding of VDR–RXR heterodimers (Fig. S4B) and thus
were omitted from further investigations.
In summary, in reporter gene analysis only the IL-12B promoter
regions 5 and 17 showed signiﬁcant, 1α,25(OH)2D3-dependent
down-regulation. Only RE2 (region 5) and RE5 (region 17) showed
in vitro VDR–RXR heterodimer binding.
3.4. Cyclical association of repressive protein complexes to 1α,25
(OH)2D3 responsive regions of the IL-12B gene
To further investigate the role of REs 2 and 5 in the repression of IL-
12B, we performed in THP-1 cells quantitative ChIP analysis of the
effect of 1α,25(OH)2D3 on the recruitment of VDR, RXR, HDAC3 and
NCOR2/SMRT to regions 5 and 17 in 10 min intervals over 100 min
(Fig. 4). NCOR2/SMRTwas chosen, since VDR–RXR heterodimers have
been reported to associate preferably with NCOR2/SMRT than with
NCOR1 [37,38]. The TSS region of the IL-12B gene served as a
reference. VDR and RXR were enriched at all three regions at time
periods 20–30 min and 60–80 min, which to a great extent was
followed by the recruitment of HDAC3 and NCOR2/SMRT. Instead, no
signiﬁcant association of co-activator SRC1 could be observed within
any regions in the absence or in the presence of hormone suggesting
that the RE2 and RE5 mediated only repressive effects (Fig. S5).
Taken together, within a measuring period of 100 min two 1α,25
(OH)2D3-dependent cycles of recruitment of VDR, RXR and repressive
proteins HDAC and NCOR2/SMRT to regions 5 (RE2) and 17 (RE5) and
the TSS were observed.
3.5. 1α,25(OH)2D3-dependent epigenetic changes within the IL-12B gene
The 1α,25(OH)2D3-dependent recruitment of repressive proteins,
such as HDAC3 and NCOR2/SMRT, to regulatory regions of the IL-12B
gene suggested that 1α,25(OH)2D3 treatmentmay cause a shift from a
permissive to a less permissive chromatin status at these regions. In
order to challenge this hypothesis, we performed quantitative ChIP
analysis with antibodies against H4ac and H3K27me3 (Fig. 5). In a
similar time course as in the previous experiment, the changes in
chromatin status were assessed every 10 min after onset of ligand
treatment. H4ac levels, which are marks of active chromatin,
decreased signiﬁcantly at region 5 and the TSS within the ﬁrst 30–
40 min and remained at low level for the remainingmeasuring period.
In contrast, for the repressive mark, H3K27me3, the levels went up on
the same two regions with a maximum reached after 70–90 min. The
effects observed on region 17 showed for both epigenetic marks the
same tendency as for region 5 and the TSS, but they were less
prominent.In summary, 1α,25(OH)2D3 treatment resulted in signiﬁcant
epigenetic changes leading to chromatin repression on region 5
(containing RE2) and the TSS, which are to a lower extent followed by
that on region 17 (containing RE5).
4. Discussion
IL-12 is a pro-inﬂammatory cytokine that connects innate and
adaptive immune responses by stimulating the development of Th1
cells and thus enhancing the immune response against intracellular
pathogens. Therefore, IL-12 expression is vital for functional immune
system and survival in vertebrates, but over-expression of IL-12 can
also lead to serious diseases [5,6]. Another cytokine, IL-23, having IL-
12B as a common subunit with IL-12, is necessary for T cell-dependent
inﬂammation, and similarly the over-expression of IL-23 has been
associated with several autoimmune diseases [33]. The mechanism of
transcriptional activation of IL-12B has been extensively studied and a
number of up-regulating elements have been located at the proximal
promoter of IL-12B, but the molecular mechanisms of transcriptional
repression of this gene are still unclear.
Inhibition of IL-12BmRNAexpression by 1α,25(OH)2D3 treatment is
well documented [9,23,24], but functional VDREswithin IL-12B genehas
not been reported before. In this study, we examined a genomic region
from−10,010 bp to +1938 bp relative to IL-12B TSS using ChIP and in
817P. Gynther et al. / Biochimica et Biophysica Acta 1813 (2011) 810–818silico analysis in order to locate the putative VDREs, via which the
repressive effects of 1α,25(OH)2D3 are mediated. We found that the IL-
12B promoter contains a DR3-type VDRE at position−488 to−460 bp
(RE2) and an ER6-type element at position−6303 to−6274 bp (RE5).
Both elements appeared to be functional in vitro and in vivo, although
the more proximal element (RE2) was clearly more potent. Interest-
ingly, Weinmann and co-workers [25] reported that murine IL-12B
promoter contains positioned nucleosomes approximately 350 and
550 bp upstream of the TSS. We observed that this region is highly
acetylated in the absence of 1α,25(OH)2D3 indicating that at this region
chromatin is in the “open” form. Together these data suggest that in the
actively transcribed IL-12B gene, RE2 should be readily accessible toVDR
binding.
Both RE2 and RE5 recruited ligand-dependently HDAC3 and
NCOR2/SMRT, which are components of a large repressive protein
complex. The activity of this complex leads to decreased histone
acetylation (i.e. lower H4ac levels) and increased histone methylation
(i.e. higher H3K27me3 levels) at different regions of the IL-12B gene
including the TSS and regions 5 and 17 containing functional VDREs.
H3K27me3 modiﬁcation is linked to permanently silenced genes, for
example those related to early phases of development. Interestingly,
Roh and co-workers reported recently a group of gene promoters that
have this modiﬁcation simultaneously with activating histone
modiﬁcations H3K9acK14ac and H3K4me3 in primary human T cells
[39]. The activity of genes within above group appeared to be
dependent on absolute and relative levels of activating and repressive
histone modiﬁcations. According to our data, IL-12B belongs to the
above group of genes and we assume that the level of activating
versus repressing histone modiﬁcations is a possible explanation for
the observed decrease in IL-12B mRNA synthesis.
1α,25(OH)2D3-dependent IL-12B repression has been suggested to
be an indirect effect resulting in VDR association with NF-κB binding
sites that would interfere with the binding of NF-κB components to
proximal IL-12B promoter [9]. However, our data suggest a slightly
different mechanism where repressive complexes that are recruited
to VDREs upstream of the NF-κB site change the chromatin
environment at proximal promoter to non-permissive form. This
may prevent recruitment of NF-κB components to proximal IL-12B
promoter and via that cause the repression.
The recruitment of VDR, RXR, HDAC3 and NCOR2/SMRT to the
regions of RE2 and RE5 showed a cyclical pattern. In this respect, the
mechanism of transcriptional regulation of IL-12B had similar features
as transcriptional mechanisms of a number of both positively
regulated VDR target genes, such as CDKN1A [26], CYP24 [27], and
IGFBP3 [36], but also of negatively regulated genes, such as MYC [28]
and IL-10 [21]. The cyclic behavior at the IL-12B promoter is mirrored
by the mRNA levels, which also showed a clear periodicity.
Importantly, the 1α,25(OH)2D3-dependent repression of IL-12B
expression could also be observed in primary monocytes. The repression
of the IL-12B gene was clearly due to 1α,25(OH)2D3 treatment, since
silencing of VDR by siRNA prevented the repression. In order to model
inﬂammation, THP-1 cells were primed with LPS before 1α,25(OH)2D3
treatmentandLPSwasalsopresent throughoutexpressionproﬁling. Thus,
the IL-12B gene was constantly activated and 1α,25(OH)2D3-dependent,
cyclic recruitment of repressive protein complexes resulted in temporal
stalls in mRNA synthesis. This could be observed as periodic decreases of
IL-12B mRNA levels due to degradation of mRNA. This suggests that at
early state of inﬂammation, 1α,25(OH)2D3 appears to control IL-12B
mRNA synthesis to prevent over-expression of IL-12. Interestingly, the
main down-regulating agent for IL-12B expression, the cytokine IL-10, is
also under direct control of 1α,25(OH)2D3 [21]. However, the 1α,25
(OH)2D3-dependent up-regulation of IL-10 takes place after longer ligand
treatment times, such as 24 h [17,21,29,30]. Thus, 1α,25(OH)2D3 appears
to have dual effect on the expression of IL-12B. At the beginning of
inﬂammation, the primary effect of 1α,25(OH)2D3 is cyclical down-
regulationof IL-12Bexpression, inorder tokeep themagnitudeof immuneresponse on acceptable level, and later a secondary effect via IL-10 occurs
that turns the IL-12B gene off. Thiswould prevent tissue damage resulting
from prolonged inﬂammation.
In conclusion, this study reveals two VDREs at position −488 to
−460 bp and −6303 to −6274 bp upstream of the IL-12B TSS, via
which the primary, repressive effects of 1α,25(OH)2D3 are mediated
during the ﬁrst hours of inﬂammation. The primary effects consist of
cyclic recruitment of repressive protein complexes to the above
elements, which cause repressive bursts that slow down IL-12BmRNA
synthesis thus preventing over-expression of IL-12 and IL-23.
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